Show Summary Details
- In Memoriam
- Foreword to the First Edition
- Preface to the Second Edition
- Preface to the First Edition
- Contributors
- IBiological Bases of Pediatric Psychopharmacology
- 1 Overview of Brain Development
- 2 Synaptic Function and Biochemical Neuroanatomy
- 3 Developmental Principles of Pharmacokinetics
- 4 Cytochrome P450-Mediated Drug Interactions
- 5 Molecular Genetics
- 6 Pharmacogenetics
- 7 Neurobiology of Attention Regulation and Its Disorders
- 8 Neurobiology of Early Life Stress: Evolving Concepts
- 9 Neurobiology of Early-onset Mood Disorders
- 10 Neurobiology of Early-onset Anxiety Disorders
- 11 Neurobiology of Obsessive-Compulsive Disorder
- 12 Neurobiological Substrates of Tic Disorders
- 13 Neurobiology of Childhood Schizophrenia and Related Disorders
- 14 Neurobiology of Autism Spectrum Disorder: Implications for Improving Pharmacotherapy
- 15 Neurobiology of Aggression
- 16 Neurobiology of Eating Disorders
- 17 Neurobiology of Substance Abuse Disorders
- II Somatic Interventions
- 18 Stimulants
- 19 <span xml:lang="ell">α</span><sub>2</sub>-Adrenergic Agonists: Clonidine and Guanfacine
- 20 Antidepressants I: Selective Serotonin Reuptake Inhibitors
- 21 Antidepressants II: Other Agents
- 22 Mood Stabilizers: Lithium, Anticonvulsants, and Others
- 23 Antipsychotic Agents: Traditional and Atypical
- 24 Anxiolytics and Sedative/Hypnotics: Benzodiazepines, Buspirone, and Others
- 25 Complementary and Alternative Medicine in Pediatric Psychopharmacology
- 26 Electroconvulsive Therapy, Transcranial Magnetic Stimulation, and Vagus Nerve Stimulation
- III Assessment and Treatment
- 27 Running a Pediatric Psychopharmacology Clinic
- 28 Clinical Instruments and Scales in Pediatric Psychopharmacology
- 29 Combining Pharmacotherapy and Psychotherapy: An Evidence-based Approach
- 30 Thinking About Prescribing: The Psychology of Psychopharmacology
- 31 Assessment and Treatment of Attention-Deficit Hyperactivity Disorder
- 32 Assessment and Treatment of Child and Adolescent Depressive Disorders
- 33 Assessment and Treatment of Childhood and Adolescent Bipolar Disorder
- 34 Assessment and Treatment of Child and Adolescent Anxiety Disorders
- 35 Assessment and Treatment of Obsessive-Compulsive Disorder
- 36 Assessment and Treatment of Tourette Syndrome and Other Tic Disorders
- 37 Assessment and Treatment of Early-onset Schizophrenia Spectrum Disorders
- 38 Assessment and Treatment of Autistic and Other Pervasive Developmental Disorders
- 39 Assessment and Treatment of Post-traumatic Stress Disorder
- 40 Assessment and Treatment of Eating Disorders and Obesity
- 41 Psychopharmacology and Substance Use Disorders: A Pediatric Approach
- 42 Individuals with Intellectual Disability
- 43 Psychopharmacology in the Medically Ill Child or Adolescent
- 44 Psychopharmacology During Pregnancy: Infant Considerations
- 45 Psychopharmacological Treatment in Preschoolers
- 46 Insomnia in Children and Adolescents
- 47 Aggression
- 48 Management of Elimination and Other Pelvic Disorders: Enuresis, Encopresis, and Psychopharmacological Effects on Sexual Function
- IV Epidemiological, Research, and Methodological Considerations
- 49 Pediatric Psychopharmacoepidemiology: Who Is Prescribing? And For Whom, How, and Why?
- 50 Clinical Trials Methodology and Designs
- 51 Regulatory Issues
- 52 Ethical Issues in Pediatric Psychopharmacology
- 53 Conflict of Interest
- 54 International Patterns of Pediatric Medication for Emotional and Behavioral Disorders
- Appendix: Psychopharmacology at a Glance
- Disclosures of Financial Interests
- Index
(p. 297) Mood Stabilizers: Lithium, Anticonvulsants, and Others
(p. 297)
Mood Stabilizers: Lithium, Anticonvulsants, and Others
- Chapter:
- (p. 297) Mood Stabilizers: Lithium, Anticonvulsants, and Others
- Author(s):
Robert A. Kowatch
, Jeffrey R. Strawn
, and Arman Danielyan
- DOI:
- 10.1093/med/9780195398212.003.0022
Chapter 22 reviews the mechanism of action of mood stabilizers, which can be divided into the traditional agents — lithium, valproate, and carbamazepine — and the newer or “novel” agents, which include lamotrigine, oxcarbazepine, topiramate, gabapentin, and pregabalin, and the pharmacokinetic and clinical factors important to be aware of when these agents are used to treat children and adolescents.
Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.
Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.
- In Memoriam
- Foreword to the First Edition
- Preface to the Second Edition
- Preface to the First Edition
- Contributors
- IBiological Bases of Pediatric Psychopharmacology
- 1 Overview of Brain Development
- 2 Synaptic Function and Biochemical Neuroanatomy
- 3 Developmental Principles of Pharmacokinetics
- 4 Cytochrome P450-Mediated Drug Interactions
- 5 Molecular Genetics
- 6 Pharmacogenetics
- 7 Neurobiology of Attention Regulation and Its Disorders
- 8 Neurobiology of Early Life Stress: Evolving Concepts
- 9 Neurobiology of Early-onset Mood Disorders
- 10 Neurobiology of Early-onset Anxiety Disorders
- 11 Neurobiology of Obsessive-Compulsive Disorder
- 12 Neurobiological Substrates of Tic Disorders
- 13 Neurobiology of Childhood Schizophrenia and Related Disorders
- 14 Neurobiology of Autism Spectrum Disorder: Implications for Improving Pharmacotherapy
- 15 Neurobiology of Aggression
- 16 Neurobiology of Eating Disorders
- 17 Neurobiology of Substance Abuse Disorders
- II Somatic Interventions
- 18 Stimulants
- 19 <span xml:lang="ell">α</span><sub>2</sub>-Adrenergic Agonists: Clonidine and Guanfacine
- 20 Antidepressants I: Selective Serotonin Reuptake Inhibitors
- 21 Antidepressants II: Other Agents
- 22 Mood Stabilizers: Lithium, Anticonvulsants, and Others
- 23 Antipsychotic Agents: Traditional and Atypical
- 24 Anxiolytics and Sedative/Hypnotics: Benzodiazepines, Buspirone, and Others
- 25 Complementary and Alternative Medicine in Pediatric Psychopharmacology
- 26 Electroconvulsive Therapy, Transcranial Magnetic Stimulation, and Vagus Nerve Stimulation
- III Assessment and Treatment
- 27 Running a Pediatric Psychopharmacology Clinic
- 28 Clinical Instruments and Scales in Pediatric Psychopharmacology
- 29 Combining Pharmacotherapy and Psychotherapy: An Evidence-based Approach
- 30 Thinking About Prescribing: The Psychology of Psychopharmacology
- 31 Assessment and Treatment of Attention-Deficit Hyperactivity Disorder
- 32 Assessment and Treatment of Child and Adolescent Depressive Disorders
- 33 Assessment and Treatment of Childhood and Adolescent Bipolar Disorder
- 34 Assessment and Treatment of Child and Adolescent Anxiety Disorders
- 35 Assessment and Treatment of Obsessive-Compulsive Disorder
- 36 Assessment and Treatment of Tourette Syndrome and Other Tic Disorders
- 37 Assessment and Treatment of Early-onset Schizophrenia Spectrum Disorders
- 38 Assessment and Treatment of Autistic and Other Pervasive Developmental Disorders
- 39 Assessment and Treatment of Post-traumatic Stress Disorder
- 40 Assessment and Treatment of Eating Disorders and Obesity
- 41 Psychopharmacology and Substance Use Disorders: A Pediatric Approach
- 42 Individuals with Intellectual Disability
- 43 Psychopharmacology in the Medically Ill Child or Adolescent
- 44 Psychopharmacology During Pregnancy: Infant Considerations
- 45 Psychopharmacological Treatment in Preschoolers
- 46 Insomnia in Children and Adolescents
- 47 Aggression
- 48 Management of Elimination and Other Pelvic Disorders: Enuresis, Encopresis, and Psychopharmacological Effects on Sexual Function
- IV Epidemiological, Research, and Methodological Considerations
- 49 Pediatric Psychopharmacoepidemiology: Who Is Prescribing? And For Whom, How, and Why?
- 50 Clinical Trials Methodology and Designs
- 51 Regulatory Issues
- 52 Ethical Issues in Pediatric Psychopharmacology
- 53 Conflict of Interest
- 54 International Patterns of Pediatric Medication for Emotional and Behavioral Disorders
- Appendix: Psychopharmacology at a Glance
- Disclosures of Financial Interests
- Index
